methotrexate + teniposide + PEG-asparaginase

This is a **combination chemotherapy regimen** composed of methotrexate, teniposide, and PEG-asparaginase. Each agent in this combination targets leukemic cells through a distinct mechanism: - **Methotrexate** is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, leading to impaired DNA synthesis and cell death. - **Teniposide** is a topoisomerase II inhibitor that induces DNA breaks, disrupting cell replication. - **PEG-asparaginase** is a pegylated form of L-asparaginase that depletes extracellular asparagine, an amino acid essential for the survival of certain leukemic cells, particularly those with low asparagine synthetase activity. PEGylation of asparaginase extends its half-life and reduces immunogenicity compared to native asparaginase. This combination is primarily used in **multi-agent chemotherapy regimens for acute lymphoblastic leukemia (ALL)**, including relapsed or refractory cases, and occasionally in high-risk lymphoblastic lymphomas. It is administered as part of rotating chemotherapy “blocks” during intensive phases of treatment. The combination exploits complementary mechanisms of cytotoxicity and can be tailored in terms of dosage and scheduling to optimize anti-leukemic effects, although toxicities such as myelosuppression, hypersensitivity reactions (especially to asparaginase), and infection risk remain clinically relevant[5][1][2][3].

Other names

methotrexate + teniposide + PEG-asparaginasemethotrexate + teniposide + pegylated L-asparaginase